AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Amer M. Zeidan, Jörg Westermann, Tibor Kovacsovics, Sarit Assouline, Andre C. Schuh, Hee‐Je Kim, Gabriela Rodríguez Macias, David Sanford, Marlise R. Luskin, Eytan M. Stein, Kamel Malek, Jiaying Lyu, Mario Stegert, Jordi Esteve
Topics & Concepts
VenetoclaxMedicineAzacitidineCohortInternal medicineNeutropeniaMyeloid leukemiaMyeloidMyelodysplastic syndromesOncologyHypomethylating agentTolerabilityLeukemiaGastroenterologyChemotherapyAdverse effectChronic lymphocytic leukemiaBone marrowChemistryBiochemistryGene expressionGeneDNA methylationAcute Myeloid Leukemia ResearchPneumocystis jirovecii pneumonia detection and treatmentMyeloproliferative Neoplasms: Diagnosis and Treatment